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Abstract
Background: β-synemin was originally identified in humans as an α-dystrobrevin-binding protein through
a yeast two-hybrid screen using an amino acid sequence derived from exons 1 through 16 of α-
dystrobrevin, a region common to both α-dystrobrevin-1 and -2. α-Dystrobrevin-1 and -2 are both
expressed in muscle and co-localization experiments have determined which isoform preferentially
functions with β-synemin in vivo. The aim of our study is to show whether each α-dystrobrevin isoform
has the same affinity for β-synemin or whether one of the isoforms preferentially functions with β-synemin
in muscle.
Methods: The two α-dystrobrevin isoforms (-1 and -2) and β-synemin were localized in regenerating rat
tibialis anterior muscle using immunoprecipitation, immunohistochemical and immunoblot analyses.
Immunoprecipitation and co-localization studies for α-dystrobrevin and β-synemin were performed in
regenerating muscle following cardiotoxin injection. Protein expression was then compared to that of
developing rat muscle using immunoblot analysis.
Results: With an anti-α-dystrobrevin antibody, β-synemin co-immunoprecipitated with α-dystrobrevin
whereas with an anti-β-synemin antibody, α-dystrobrevin-1 (rather than the -2 isoform) preferentially co-
immunoprecipitated with β-synemin. Immunohistochemical experiments show that β-synemin and α-
dystrobrevin co-localize in rat skeletal muscle. In regenerating muscle, β-synemin is first expressed at the
sarcolemma and in the cytoplasm at day 5 following cardiotoxin injection. Similarly, β-synemin and α-
dystrobrevin-1 are detected by immunoblot analysis as weak bands by day 7. In contrast, immunoblot
analysis shows that α-dystrobrevin-2 is expressed as early as 1 day post-injection in regenerating muscle.
These results are similar to that of developing muscle. For example, in embryonic rats, immunoblot
analysis shows that β-synemin and α-dystrobevin-1 are weakly expressed in developing lower limb muscle
at 5 days post-birth, while α-dystrobrevin-2 is detectable before birth in 20-day post-fertilization embryos.
Conclusion: Our results clearly show that β-synemin expression correlates with that of α-dystrobrevin-
1, suggesting that β-synemin preferentially functions with α-dystrobrevin-1 in vivo and that these proteins
are likely to function coordinately to play a vital role in developing and regenerating muscle.
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Synemin is a muscle intermediate filament protein that
was originally identified in chickens [1]. Recently, human
α- and β-synemin orthologues have been cloned [2,3], the
latter of which was previously termed human desmuslin
[2]. Both human synemin isoforms derive from the same
gene as a result of differential splicing between exons 4
and 5 such that the β-synemin protein is 312 amino acids
shorter at its C-terminus [4]. Both the β-synemin mRNA
and protein are highly expressed in skeletal and cardiac
muscle, while northern blot analysis also shows a weak
doublet in brain [2], indicating that there are at least two
different synemin isoforms expressed in that tissue. In
humans, α-synemin is expressed in astrocytes of the optic
nerve and in non-myelin-forming Schwann cells [5]. β-
synemin was originally isolated in humans as an α-dystro-
brevin- and desmin-interacting protein [2], two proteins
expressed in differentiated muscle cells. Subsequent
immunohistochemical analysis has shown that β-syne-
min localizes in human skeletal muscle to the costamere,
the neuromuscular and myotendinous junctions, the Z-
lines, and along the sarcolemma [2,4]. Although 12 differ-
ent amino acid altering single-nucleotide polymorphisms
have been identified within β-synemin's coding region,
no causative mutations have yet been linked to a disease
[6]; however, this gene is still a good disease candidate for
myopathies of unknown etiology.
α-Dystrobrevin is one of the components of the dys-
trophin-associated protein complex (DAPC) [7] and inter-
acts specifically with dystrophin and syntrophin in
skeletal muscle [8]. The DAPC is thought to function as a
structural link between the extracellular matrix and the
internal cytoskeleton, although recently there has been
speculation that the complex may also be involved in
some type of signaling pathway. Interestingly, neuronal
nitric oxide synthase (nNOS) levels have been shown to
be significantly reduced in α-dystrobrevin-deficient mus-
cle [9]. Through alternative splicing, α-dystrobrevin is
expressed in several isoforms with α-dystrobrevin-1, -2,
and -3 being the most highly expressed in skeletal muscle
[7]. α-Dystrobrevin-1 is the largest isoform and has a
unique 189 amino acid C-terminus, whereas α-dystrobre-
vin-2 is slightly smaller and contains a unique 16 amino
acid C-terminus. The amino acid sequence originally used
as the two-hybrid "bait" to isolate β-synemin was a
sequence shared between α-dystrobrevin-1 and -2 [2]. It is
therefore possible that both types of α-dystrobrevin inter-
act with β-synemin, although one isoform of α-dystrobre-
vin might preferentially interact with β-synemin in vivo.
Recently, Hoshino et al. examined the expression of many
DAPC proteins in regenerating rat tibialis anterior muscle
following cardiotoxin injection [10-13]. Using western
blot analysis, they found that β-dystroglycan was
expressed very early during muscle regeneration and
reached half-maximal expression within 1 day following
cardiotoxin injection [11]. Dystrophin was first detected
at day 3 and reached half-maximal expression by day 5.3
[10-13]. α-Sarcoglycan reached half-maximal expression
at day 4.3 [11], α1-syntrophin at day 6.0 [10], α-dystro-
brevin-1 at day 6.6 [12], and nNOS at day 11.7 [13]. This
data suggested that protein reexpression during muscle
regeneration occurred in an ordered fashion based on pro-
tein location. For example, proteins expressed within the
basement membrane were expressed earlier than subsar-
colemmal proteins, although even there, structural pro-
teins (like dystrophin) were expressed earlier than
proteins associated with signaling (such as α1-syntrophin,
α-dystrobrevin-1, and nNOS). Expression data for β-syne-
min and α-dystrobevin-2 was not reported.
To better understand the role of β-synemin in muscle, we
used co-immunoprecipitation, co-localization, and time-
course experiments to monitor the expression of β-syne-
min and α-dystrobrevin in regenerating and developing
rat tibialis anterior muscle. By correlating β-synemin
expression with the reported expression patterns for dys-
trophin and its associated proteins [10-13], it is possible
to start to dissect the function of β-synemin in muscle.
Specifically, we correlate β-synemin expression with α-
dystrobrevin-1 and -2, two potential β-synemin-interact-
ing proteins. Our experiments show that β-synemin
expression highly correlates with that of α-dystrobrevin-1
in developing and regenerating muscle, suggesting that β-
synemin is more likely to coordinately function with α-
dystrobrevin-1 than α-dystrobrevin-2 in vivo.
Methods
Animal care
Male Wistar rats (7 weeks old, 170–190 g, n = 48) were
obtained from CLEA Japan, Inc., Tokyo. For the duration
of the experiment, the rats were housed with 2 to 3 ani-
mals per cage and were kept at a constant temperature of
25°C with a 12-hour-light/dark cycle. All animal proto-
cols required for this study were approved by the Institu-
tional Animal Welfare Committee of the Animal
Experiment Center at the University of Tsukuba. Female
Wistar rats pregnant with 16-day-old and 18-day-old
unborn embryos and female Wistar rats with 1-day-old, 3-
day-old, 5-day-old, and 7-day-old pups were obtained
from CLEA Japan, Inc., Tokyo.
Immunoprecipitation
Protein extracts from rat tibialis anterior muscle taken 21
days after cardiotoxin injection were prepared by homog-
enization in 10 volumes of ice-cold RIPA buffer, pH 7.4,
containing freshly added protease inhibitors (0.1 mM
PMSF, 1 mg/ml each of antipain, leupeptin, aprotinin,
and pepstatin A) followed by centrifugation at 1,000xGPage 2 of 10
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for each immunoprecipitation. 15 μl of either a rabbit
polyclonal anti-β-synemin antibody [4] or a mouse mon-
oclonal anti-α-dystrobrevin antibody (BD Transduction
Laboratories, Lexington, KY, USA) and 50 μl of 50% Pro-
tein G Sepharose 4 Fast Flow (GE Healthcare, Tokyo,
Japan) were added as indicated and incubated for 16
hours at 4°C with rotation. Immunoprecipitants were
separated by sodium dodecylsulfate (SDS)-polyacryla-
mide gel electrophoresis, and the gel was probed by west-
ern blotting with either the anti-α-dystrobrevin antibody
or the anti-β-synemin antibody as indicated.
Cardiotoxin injection
Animals were temporarily anesthetized with an inhala-
tion of diethyl ether and an intraperitoneal injection con-
taining pentobarbital sodium (60 mg/kg). For assaying
muscle recovery, a single dose of cardiotoxin (1 ml of a 2
μM stock) from the Taiwan cobra, Naja naja atra (Latoxan,
Valence, France), was injected intramuscularly into the
right tibialis anterior muscle of 24 rats. As a control, the
contralateral muscles were injected in the same animals
with sterile 0.9% saline. After injection, the animals were
returned to their cages and allowed free access to food and
water.
Muscle sampling
Rats were anesthetized using diethyl ether inhalation and
a subsequent intraperitoneal injection of pentobarbital
sodium (60 mg/kg). After removal of their injected mus-
cles, the rats were euthanized with an intraperitoneal
injection of an overdose of pentobarbital sodium. For
examination, cardiotoxin-injected muscles were removed
from each of the 9 tibialis anterior muscles on days 1, 3,
5, 7, 10, 14, 21 and 28 post-injection.
Preparation of muscles for histochemical and 
immunohistochemical analyses
Biopsied muscles were immersed in OCT and frozen in
chilled isopentane cooled by liquid nitrogen. Serial frozen
sections were prepared at 10 μm and used for immunohis-
tochemical and ATPase staining. For immunohistochemi-
cal analysis, sections were blocked in a solution supplied
in the ABC-kit (avidin-biotinylated enzyme complex
method; Vector Laboratories, Burlingame, CA, USA) for
20 minutes at room temperature and incubated overnight
at 4°C with the anti-β-synemin antibody [4] diluted
1:1000 in hybrization solution provided in the ABC-kit.
The slides were washed 3 times for 10 minutes each in ice-
cold 1xPBS and then incubated with a donkey anti-rabbit
Cy3-conjugated secondary antibody (Jackson ImmunoRe-
search Laboratories, West Grove, PA, USA) for 1 hour at
room temperature. The slides were washed 3 times for 10
minutes each in ice-cold 1xPBS before mounting in
vectashield. The slides were analyzed using an Axiophoto
2 (Carl Zeiss, Oberkochen, Germany) fluorescent micro-
scope.
For confocal analysis of β-synemin and α-dystrobrevin,
sections were prepared from rat tibialis anterior muscle
sectioned 21 days after cardiotoxin injection. Sections
were incubated overnight at 4°C with a mix of the anti-β-
synemin antibody and the anti-α-dystrobrevin antibody
(BD Transduction Laboratories), an antibody that recog-
nizes both the type 1 and type 2 α-dystrobrevin isoforms.
The slides were washed 3 times for 10 minutes each in ice-
cold 1xPBS and then incubated with a mix of a donkey
anti-rabbit Cy3-conjugated secondary antibody (Jackson
ImmunoResearch Laboratories) for β-synemin and a goat
anti-mouse IgG-biotin followed by Streptavidin-fluores-
cein (Amersham Pharmacia Biotech, Buckinghamshire,
UK) for α-dystrobrevin. After washing in 1xPBS the sec-
tions were mounted in 90% glycerol in 1xPBS. A Leica DM
IRB with TNC-NT confocal scanning laser microscope
(Leica TCS SP/DM IRB inverted confocal scanning micro-
scope; Leica Microsystems GmbH, Wetzlar, Germany) was
used for the confocal microscopy recordings.
For ATPase analysis, serial sections were preincubated at
pH 4.3, 4.6, and 10.4, respectively. Then, sections were
incubated in ATP solutions (75 mg ATP disodium salt in
9.47 mM calcium chloride and 21 mM sodium barbital)
for 25 minutes at room temperature. After washing with
1% calcium chloride, the slides were incubated in 2%
cobalt chloride for 10 minutes and developed in a 1%
ammonium sulfide solution for 30 seconds following
washing in 0.1 M sodium barbital solutions. After dehy-
dration in ascending alcohols (50%, 70%, 80%, 95%x2,
100%x2), slides were mounted with canada balsam.
Immunoblot analysis
10 μm cross-sections of cardiotoxin-injected tibialis ante-
rior muscle were stained with hematoxylin and eosin to
assay for degenerating or regenerating fibers. For electro-
phoretical analysis, cardiotoxin affected tissue was physi-
cally excised from the section using a scalpel and protein
extracts were prepared (total amount: 20–50 mg) by
homogenizing excised tissue fragments in 20 volumes of
ice-cold RIPA buffer (pH 7.4) containing freshly added
protease inhibitors (0.1 mM PMSF, 1 mg/ml each of
antipain, leupeptin, aprotinin, and pepstatin A). Insolu-
ble particles were removed by centrifugation at 1000xG
for 10 minutes at 4°C. Protein concentration was meas-
ured using a bicinchoninic acid protein assay (Pierce,
Rockford, IL, USA). 5 μl of each extract (4.0 mg protein/
ml) was separated on a 10% sodium dodecylsulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE). Proteins were
transferred to Hybond-P membranes (Amersham Phar-
macia Biotech) in transfer buffer (25 mM Tris/192 mM
glycine/20% v/v methanol, pH 8.3) at 30 V for 16 hoursPage 3 of 10
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Hercules, CA, USA). Membranes were blocked with 5% w/
v skimmed dried milk powder in Tris buffered saline (20
mM Tris, 137 mM NaCl, pH 7.6) plus 0.1% Tween 20
(TBST) for 1 hour at room temperature, washed three
times with TBST, and probed for 2 hours with either the
anti-β-synemin [4] or the anti-α-dystrobrevin (1:200 dilu-
tion, BD Transduction Laboratories) primary antibody.
Membranes were washed three times with TBST and then
incubated for 1 hour with horseradish peroxidase (HRP)-
conjugated donkey anti-rabbit IgG (H + L) secondary anti-
body for β-synemin staining or horseradish peroxidase
(HRP)-linked sheep anti-mouse whole IgG secondary
antibody for α-dystrobrevin staining (GE Healthcare,
Tokyo, Japan). The membrane was washed in TBST and
the HRP-conjugated protein was detected by ECL accord-
ing to the manufacturers instructions (Amersham Phar-
macia Biotech). To verify that each lane was loaded with
equal amounts of protein (see above for protein quantifi-
cation), the intensity of non-specific background bands
was compared in the immunoblots being analyzed.
To assay protein expression during development, crude
muscle was obtained from the whole lower limb of rats at
embryonic day 16 and 18, whole distal lower limb mus-
cles were isolated at embryonic day 20 and 1 day-old rats,
and partial back portions of distal lower limb muscles
were prepared from 3-, 5-, and 7-day-old and adult rats.
Excised muscles were weighed and suspended in 20 vol-
umes (w/v) of loading buffer containing 70 mM Tris-HCl
(pH 6.7), 10% SDS, 10 mM ethylenediamine tetraacetic
acid, and 5% β-mercaptoethanol. Suspensions were
boiled for 5 minutes, left at room temperature for 10 min-
utes, and clarified by centrifugation at 15,000 rpm for 10
minutes at room temperature. Proteins were separated by
SDS-PAGE on 5–15% acrylamide gels (Bio Craft, Tokyo,
Japan), transferred to Hybond-P membranes (Amersham
Pharmacia Biotech) in transfer buffer (48 mM Tris/39 mM
glycine/13 mM SDS/20% methanol) at 15 V for 20 min-
utes using a Trans-Blot SemiDry apparatus (Bio Rad Lab-
oratories), and blocked with blocking buffer (0.1%
gelatin/0.1% casein/1xPBS) for 1 hour at 4°C. Blots were
probed for 2 hours simultaneously with antibodies
against β-synemin (1:1,000) and α-dystrobrevin
(1:2,000). Membranes were washed with 0.1% Tween 20/
1xPBS for 1 hour, and then incubated for 1 hour with a
mix of horseradish peroxidase (HRP)-conjugated donkey
anti-rabbit IgG (H + L) and anti-mouse IgG (H + L) sec-
ondary antibodies (Jackson ImmunoResearch Laborato-
ries) in blocking buffer with 0.1% Tween 20. The
membrane was washed in 0.1% Tween 20/1xPBS for 1
hour and the HRP-conjugated protein was detected using
ECL+plus reagent (Amersham Pharmacia Biotech). To
verify that each lane was loaded with equal amounts of
protein, the intensity of non-specific background bands
was compared in the immunoblots being analyzed.
Quantitation of immunoblots
Densitometry was used to obtain quantitative data from
western blots. HyperfilmECL film (Amersham Pharmacia
Biotech) was scanned at an optical resolution of 400 dpi
using an Epson GT9500 flatbed scanner. Densitometric
analysis for each blot was performed with a computerized
image processing system (NIH image 1.62). Previous
experiments have shown this system yields densitometry
measurements that are linear with respect to the amount
of protein analyzed [10-13]. The relative protein levels on
days 1 and 28 were set at 0% and 100%, respectively. For
each of the other days, the relative protein levels were
determined based on the density of the band relative to
that on day 28. The mean relative protein level + SD on
each day (n = 6–9) was plotted on sequential lines.
Results
To determine if β-synemin and α-dystrobrevin interact in
vivo, co-immunoprecipitation experiments were per-
formed from rat muscle homogenates prepared 21 days
after the cardiotoxin injection. At this developmental
stage, both β-synemin (Fig. 1A, lane 1) and α-dystrobre-
vin (Fig. 1B, lane 1) are expressed. Using an anti-α-dystro-
brevin antibody, β-synemin co-immunoprecipitated and
was detectable by western blot analysis (Fig. 1A, lane 2)
and was not present in the supernatant after immunopre-
cipitation (Fig. 1A, lane 3). Similarly, using an anti-β-syn-
emin antibody, both α-dystrobrevin-1 and -2 co-
precipitated reconfirming an interaction between β-syne-
min and α-dystrobrevin (Fig. 1B, lane 2). However, no α-
dystrobrevin-1 remained in the supernatant after immu-
noprecipitation with the anti-β-synemin antibody, while
some of the α-dystrobrevin-2 protein did (Fig. 1B, lane 3).
These results suggest that the interaction between β-syne-
min and α-dystrobrevin-1 is stronger than that between β-
synemin and α-dystrobrevin-2.
To examine the co-localization of α-dystrobrevin and β-
synemin in vivo, double immunostaining was performed
using the rat tibialis anterior muscle sectioned 21 days
after cardiotoxin injection. When the section was stained
with an anti-α-dystrobrevin antibody, the muscle cell
membrane was homogeneously immunostained (Fig. 1C,
left panel) whereas β-synemin was irregularly immunop-
ositive along the sarcolemma in addition to the cytoplasm
(Fig. 1C, center panel). Merging the two images confirms
that they are co-localized, at least where β-synemin is
expressed at the sarcolemma (Fig. 1C, right panel).
Although α-dystrobrevin is expressed at the sarcolemma
like dystrophin, staining also suggests some expression in
the cytoplasm (Fig. 1C, right panel).Page 4 of 10
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2007, 8:40 http://www.biomedcentral.com/1471-2474/8/40Expression patterns for dystrophin, α1-syntrophin, α-dys-
trobrevin-1, neuronal nitric oxide synthase, α-sarcogly-
can, and β-dystroglycan have been reported for
regenerating rat muscle [10-13]. By using this same
model, it is possible to directly correlate β-synemin's
expression with other muscle proteins in regenerating and
developing muscle to better understand β-synemin's role
in muscle. Cardiotoxin injection is a well-established
method to assay muscle regeneration in adult tissue.
Using this assay, it is possible to identify proteins that are
activated in response to injury. We injected cardiotoxin
into the right tibialis anterior muscle in 24 rats. As a con-
trol, contralateral muscles in the same animals were
injected with sterile 0.9% saline. Muscle was collected at
times between days 1 through 28 following injection.
Regenerating tissue was excised from the injected rats and
β-synemin and α-dystrobrevin interact in vivo and co-localize in rat muscleFigure 1
β-synemin and α-dystrobrevin interact in vivo and co-localize in rat muscle. (A) Using an anti-α-dystrobrevin antibody, α-dys-
trobrevin and its interacting proteins were immunoprecipitated from rat protein muscle extracts. Western blot analysis was 
performed to localize the β-synemin protein. β-synemin was found to be present in the muscle extract (1) and immunoprecip-
itated pellet (2), while it was not detected in the supernatant (3). (B) Using an anti-β-synemin antibody, β-synemin and its inter-
acting proteins were immunoprecipitated from rat protein muscle extracts. Western blot analysis was performed to localize 
the α-dystrobrevin isoforms. Both α-dystrobrevin-1 and -2 were detected in the muscle extract (1) and pellet (2), while only 
α-dystrobrevin-2 was present in the supernatant (3). (C) Rat tibialis anterior muscle was sectioned 21 days following cardio-
toxin injection and double immunostained with antibodies against α-dystrobrevin antibody (left panel), β-synemin (center 
panel), and the merged image (right panel). Bar = 50 μm
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and α-dystrobrevin's expression following injury. For the
first 3 days following cardiotoxin injection, β-synemin
expression was not observed either at the sarcolemma or
within the cytoplasm (Fig. 2). On the 5th day, smaller
regenerating muscles showed partial sarcolemmal and
cytoplasmic staining for β-synemin. Cytoplasmic staining
was evident by the 7th day, whereas sarcolemmal staining
became more prevalent on the 10th day. The highest level
of β-synemin expression was recorded on the 14th day
and mosaic sarcolemmal staining was apparent on the
21st and 28th days. With regard to the saline injection
control, the muscle was not damaged and showed no
changes in β-synemin expression over time (data not
shown). In addition, sarcolemmal staining appeared to be
fiber specific as some fibers stained both inside and at the
sarcolemma much stronger for β-synemin than others.
It becomes possible to distinguish between different mus-
cle fiber types in regenerating rat muscle after fourteen
days following cardiotoxin injection [13]. To determine if
β-synemin's mosaic staining pattern was dependent on
muscle fiber type, ATPase staining was performed for
muscle sectioned 21 and 28 days post-cardiotoxin injec-
tion. At 21 days post-injection, β-synemin was expressed
at the sarcolemmal membrane in type 1 and type 2C mus-
cle fibers (data not shown). At 28 days post-injection, β-
synemin was expressed at the sarcolemmal membrane in
type 1, type 2B, and type 2C muscle fibers whereas type 2A
fibers did not show sarcolemmal staining (Fig. 3).
To better quantitate β-synemin expression during muscle
regeneration, immunoblot analysis was performed for
muscles collected at different time points following cardi-
otoxin injection. In agreement with expression data from
immunohistochemistry experiments (Fig. 2), β-synemin
was detected by immunoblot assay as a weak band on day
7 following cardiotoxin injection. By immunoblot analy-
sis, β-synemin expression increased sequentially for the
first 14 days, but thereafter remained almost constant
through day 28 (Fig. 4, top panel). Similarly, α-dystrobre-
vin-1 was first detected on day 7 and its expression
remained constant through day 28 (Fig. 4, middle panel).
In contrast, α-dystrobrevin-2 expression was apparent as
early as 1 day post-injection, and reached maximal expres-
sion by day 10, almost 4 days earlier than β-synemin or α-
dystrobrevin-1. In addition, α-dystrobrevin-2's expression
decreased after day 10 (Fig. 4, bottom panel) unlike α-
dystrobrevin-1 and β-synemin.
To better quantitate these data, immunoblot analysis for
β-synemin, α-dystrobrevin-1 and -2 was densitometrically
analyzed for each time point and the relative mean pro-
tein level for each day was plotted (Fig. 5). β-synemin and
α-dystrobrevin-1 reached 50% of their 28 day's expression
level by days 6.6 and 6.2, respectively. By day 1, α-dystro-
brevin-2 was already at 75% of its expression level relative
to that expressed at 28 days. The relative protein expres-
sion level for α-dystrobrevin-2 reached its highest point
on day 10 at 175% whereupon it started to decline. These
differences suggest that α-dystrobrevin-1 and-2 serve dif-
ferent functions in regenerating muscle. Since β-synemin's
expression following injury more closely correlates with
α-dystrobrevin-1, a protein known to interact with β-syn-
emin in vitro, it suggests that these two proteins are more
likely to coordinately function in vivo than β-synemin and
α-dystrobrevin-2.
To investigate if protein expression patterns for β-syne-
min, α-dystrobrevin-1 and α-dystrobrevin-2 are similar
between muscle regeneration and development, lower-
limb muscles from rats at embryonic day 16 through 7
days post-birth were examined (Fig. 6). β-synemin and α-
dystrobrevin-1 were first expressed at 5 days post-birth,
although even then, expression was significantly less than
that of adult muscle (Fig. 6). In contrast, α-dystrobrevin-2
expression was seen before birth in 20-day-old embryos.
Expression of α-dystrobrevin-2 quickly increased such
that α-dystrobrevin-2 reached adult levels by 7 days post-
birth whereas β-synemin and α-dystrobrevin-1 were
below adult levels. Similar to that shown for regenerating
muscle, these data from developing muscle show that β-
synemin expression better correlates with α-dystrobrevin-
1 than α-dystrobrevin-2 suggesting that β-synemin was
more likely to function concordantly with α-dystrobrevin-
1 in vivo.
Discussion
Mammalian β-synemin was originally identified as an α-
dystrobrevin-binding protein through a yeast two-hybrid
screen using an amino acid sequence derived from exons
1 through 16 of α-dystrobrevin [2,14], a region common
to both α-dystrobrevin-1 and -2. Therefore, it is unknown
from this analysis, whether each α-dystrobrevin isoform
has the same affinity for β-synemin or whether one of the
isoforms functions coordinately with β-synemin in vivo.
Muscle degeneration and regeneration can be induced by
injecting bupivacaine [15], the venom of Australian tiger
snake [16], and cardiotoxin [10-13,17,18] from the Tai-
wan cobra (Naja naja atra) directly into rat muscle. Using
this assay, we analyzed β-synemin and α-dystrobrevin to
correlate their expression patterns during skeletal muscle
regeneration.
Previously, we had reported that β-synemin expression
was normal in dystrophin-deficient (mdx) muscle [4].
Whereas α-dystrobrevin-2 was greatly reduced in mdx
muscle, α-dystrobrevin-1 was unaffected [4] suggesting
that β-synemin may preferentially interact with that α-
dystrobrevin isoform in vivo. In addition, α-dystrobrevin-Page 6 of 10
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2007, 8:40 http://www.biomedcentral.com/1471-2474/8/401 predominantly localized to the crest of the neuromuscu-
lar junctions (NMJs), whereas α-dystrobrevin-2 was
expressed at the deep portions of the NMJs [19], suggest-
ing the two α-dystrobrevin isoforms may have very differ-
ent functions. By determining which isoform of α-
dystrobrevin is associated with β-synemin in vivo, we can
begin to better understand what function β-synemin
serves in developing and regenerating muscle.
This study shows that β-synemin and α-dystrobrevin-1
preferentially interact in vivo. For example, when α-dystro-
brevin was co-immunoprecipitated using an anti-β-syne-
min antibody, all of α-dystrobrevin-1 immunoprecipitated
whereas only approximately half of the α-dystrobrevin-2
isoform did (Fig. 1B). This suggests that the interaction
between β-synemin and α-dystrobrevin-1 is stronger than
that of β-synemin and α-dystrobrevin-2 although it is pos-
sible that different expression levels for the α-dystrobrevin
isoforms also could have played some role. In addition,
we also show that β-synemin expression strongly corre-
lates with α-dystrobrevin-1 (rather than α-dystrobrevin-2)
in rat muscle development and regeneration (Fig. 2, 4, 5,
6). These data strongly suggest that β-synemin associates
predominantly with the α-dystrobrevin-1 isoform.
ATPase assays are used to distinguish between muscle
fiber types. Type 1 fibers are slow-twitch fibers, whereas
type 2A and 2B fibers correspond to fast-red and fast-
white fibers, respectively [20]. Previous results have
shown that nNOS is preferentially expressed in type 2B
Immunohistochemistry of β-synemin in rat skeletal muscle after injection of cardiotoxinFigure 2
Immunohistochemistry of β-synemin in rat skeletal muscle after injection of cardiotoxin. For the first three days following 
injection, β-synemin was not detected in transverse muscle sections. β-synemin expression increased from day 5 up to day 14 
although sarcolemmal expression appeared to be more prominent on days 21 and 28. Panels are labeled with regards to the 
number of days (d) following cardiotoxin injection. Bar = 50 μm
1 d 3 d 5 d
7 d 10 d 14 d
21 d 28 dPage 7 of 10
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[13]. nNOS is thought to associate with α-dystrobrevin
[4], which in turn associates with β-synemin. While this
provides a potential explanation for fiber type specific
protein expression, the physiological significance of β-
synemin's expression in type 1, 2B, and 2C fibers rather
than 2A fibers is not fully understood; however, β-syne-
min's expression might be related to the regulation of
fatigue in type 1, 2B, and type 2C fibers.
Confocal microscopic analysis positioned β-synemin to
the costamere and muscle Z-lines [4]. In addition, β-syne-
min was enriched at the neuromuscular and myotendi-
nous junctions [4]. Based on its localization and its
expression pattern, β-synemin is thought to function as a
structural protein involved in maintaining muscle integ-
rity through its interactions with either α-dystrobrevin or
other structural proteins. Our present findings that β-syn-
emin (6.6 day) and α-dystrobrevin-1 (6.2 day) are
expressed at similar times in regenerating muscle are sim-
ilar to that previously reported for α 1-syntrophin (6.0
day) [10], suggesting that these three muscle proteins may
be involved in a common pathway. Since α 1-syntrophin
and α-dystrobrevin-1 are both involved in known signal-
ing pathways [9,21,22], it is suggestive that β-synemin is
also associated with signaling [23].
With regard to the expression patterns of β-synemin and
α-dystrobrevin during development, it should be noted
that there are instances in which the results reported here
are slightly different than that reported in the literature.
For example, Xue et al. previously demonstrated that β-
synemin was expressed at embryonic day 13 in forelimb
and hind limb of mice [24] whereas it was detected only
after 5 days post-birth in our study. In addition,
Nawrotzki et al. reported that C2 myoblasts and early
myotubes express α-dystrobrevin-1 whereas α-dystrobre-
vin-2 is only expressed in late myotubes [25]. In contrast,
we find that α-dystrobrevin-2 is expressed before birth in
20-day-old embryos whereas α-dystrobrevin-1 is
expressed only after 5 days post-birth. These differences
are hard to reconcile; however, it is possible that (1) spe-
cies differences played some role or (2) that the different
anti-α-dystrobrevin antibodies used in these studies had
slightly different specificities.
After cardiotoxin injection, α- dystrobrevin-2 and β-dys-
troglycan [11] were expressed in muscle as early as 1 day
post-injection, while α-sarcoglycan [11], dystrophin [10-
13], α 1-syntrophin [10], β-synemin, and α-dystrobrevin-
Immunohistochemistry of β-synemin and ATPase staining on uscle sec i ns after injection with c r iotoxinFigur  3
Immunohistochemistry of β-synemin and ATPase staining on 
muscle sections after injection with cardiotoxin. (A) 10 μm 
transverse muscle sections were immunostained with an 
antibody against β-synemin. (B-D) ATPase staining on serial 
sections was performed at pH 4.3 (B), pH 4.6 (C), and pH 
10.4 (D). Type 1 fibers (labeled with a "1") show strong stain-
ing at pH 4.3 and pH 4.6 and no staining at pH 10.4, whereas 
type 2A and 2B fibers (labeled with a "2A" and "2B") show 
the reverse. Type 2A fibers show weaker staining than type 
2B at pH 4.3 and pH 4.6. In addition, type 2C fibers reacted 
at pH 4.3, pH 4.6, and pH 10.4 and are under the process of 
regeneration. Bar = 50 μm
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Immunoblot analysis for β-synemin, α-dystrobrevin-1 and -2 following the i jection of cardiotoxinFigure 4
Immunoblot analysis for β-synemin, α-dystrobrevin-1 and -2 
following the injection of cardiotoxin. β-Synemin and α-dys-
trobrevin-1 were detected after day 7, whereas α-dystrobre-
vin-2 was observed as early as day 1. To normalize for 
expression levels, immunoblots for β-synemin, α-dystrobre-
vin-1 and -2 are shown from representative, but different 
experiments. Approximate molecular weights are indicated 
on the right.
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tive to its expression at day 28, β-dystroglycan was
expressed at 50% at day 1 and 100% by day 10 [11]. α-
Dystrobrevin-2 was expressed at 75% by day 1 and
increased to 130% at day 5, indicating that α-dystrobre-
vin-2 was expressed earlier in regenerating muscle than β-
dystroglycan. Since laminin persists in the basal lamina
after cardiotoxin injection [26], it is possible that β-dys-
troglycan, which indirectly binds to laminin-2 through α-
dystroglycan, is stabilized by this interaction [11]. It is
unknown how or why α-dystrobrevin-2 is expressed in the
early stages of muscle regeneration when other sarcolem-
mal proteins like dystrophin and its associated proteins
are not. What is unclear is how α-dystrobrevin-2 evades
the effects of cardiotoxin injection, although it is possible
that this isoform is somehow stable in the degenerating
fibers or that it is expressed in cells other than muscle.
Conclusion
Our results show that β-synemin and α-dystrobrevin-1 co-
localize and preferentially interact in vivo. In addition, β-
synemin and α-dystrobrevin-1 are highly up-regulated at
the same stages during muscle development and repair.
This result is in contrast to that of α-dystrobrevin-2 which
is expressed much earlier in these myogenic processes.
These data strongly suggest that β-synemin is more likely
to function with α-dystrobrevin-1 in vivo providing insight
into the possible roles of these proteins in muscle.
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